Search results
Results from the WOW.Com Content Network
With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. ... and a price target of $172. BioNTech’s oncology pipeline was ...
Citing at least 10 late-stage cancer drug studies targeted by the end of 2024, BioNTech said it mapped out plans to launch its first oncology drugs from 2026 onwards.
Price Action: BNTX stock is up 5.87% at $112.57 at the last check on Wednesday. Read Next: Regeneron/Sanofi’s Dupixent Approval Signals Major Treatment Breakthrough For Smokers’ Lung Disease
Monday’s market selloff skipped past BioNTech (BNTX). The German biotech ended the session posting a 12% gain after news that two of the COVID-19 vaccine candidates it is co-developing with ...
Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock. 5 Top Stocks to Buy in December Skip to main content
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine ...
Coronavirus is a global pandemic. With nearly 220,000 patients infected with COVID-19 at last report (according to Johns Hopkins University data), the populations of 158 countries affected, and ...
Price Action: BNTX shares are trading 9.5% higher at $201.1 in the premarket session on the last check Monday See more from BenzingaClick here for options trades from BenzingaEMA Safety Committee ...